Piper Sandler analyst Yasmeen Rahimi raised the firm's price target on Nektar to $192 from $105 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 earnings, and importantly updated on REZPEG's Phase 3 ZENITH-AD program design. Accordingly, ZENITH-AD will include five total trials, with the two biologic-naive AD studies to kick-off July 2026 with first ZENITH-AD readout mid-2028. Further, ZENITH-AD includes a third trial in biologic-experienced AD patients with initiation a "few months after" biologic-naive.
